Catheter-Directed Thrombolysis Market Outlook:
Catheter-Directed Thrombolysis Market size was valued at USD 745.6 million in 2024 and is projected to reach USD 1.9 billion by the end of 2034, growing at a CAGR of 8.7% during the forecast period 2025-2034. In 2025, the industry size of catheter-directed thrombolysis is assessed at USD 803.4 billion.
The global catheter-directed thrombolysis market is experiencing a steady rise and is driven by the patient pool suffering from venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. As per the U.S. Centers for Disease Control and Prevention, nearly 900,003 cases of venous thromboembolism are registered every year in the U.S., with 60,005 to 100,005 deaths via complications, including pulmonary embolism. As per the World Health Organization (WHO), VTE affects over 10.7 million individuals each year, highlighting the clinical need for catheter-based treatments. Further, on the supply chain side, the production pipeline involves complex logistics for both interventional radiology devices and drug APIs, and they rely on medical-grade polymers, imaging-compatible microcatheters, and biocompatible alloys.
The raw materials are sourced from countries such as Germany, India, China, and the U.S. As per the USITC trade data, the imports in the U.S. and Germany increased to 18.8% from 2020 to 2023, while the exports for thrombolytic drugs rose to 13.9% every year. The producer price index in the U.S. increased 6.4% from 2022 to 2023 for surgical and medical instruments, impacting the rising component costs. On the other hand, the consumer price index rose by 4.7% for hospital outpatient services, affecting the procurement budgets in the hospitals. In 2024, the U.S. National Institutes of Health (NIH) increased its funding for thrombosis-related research by 12.8% to over USD 95.8 million. Funding enhances the development of next-gen thrombolytics with improved efficiency via catheter systems.
Catheter-Directed Thrombolysis Market - Growth Drivers and Challenges
Growth Drivers
- Healthcare quality improvement: A 2022 Agency for Healthcare Research and Quality study revealed that early application of catheter-directed thrombolysis (CDT) minimized the hospital stays by 27.5% and saved USD 1.8 billion in aggregate nationwide inpatient costs within two years. The study further highlighted the use of CDT to reduce post-thrombotic complications and readmissions, particularly in deep vein thrombosis patients. These results urge hospitals to add CDT to institutional clinical pathways for vascular emergencies.
- Government and personal spending: In the U.S., Medicare payments for catheter-directed thrombolysis procedures reached USD 923.4 million in 2023, driven by the higher use and extended coverage under Medicare Part B. The Centers for Medicare & Medicaid Services (CMS) widened coverage under CPT code 37213 to include both pharmacologic thrombolysis and mechanical thrombectomy. At the same time, average patient out-of-pocket expenses for CDT procedures were estimated at USD 1,120.6 a year, including thrombolytic medications and catheter systems. This blend of government incentives and patient desire continues to fuel robust market expansion.
Historical Patient Growth & Its Impact on Market Dynamics
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 CDT Users (Millions) |
2020 CDT Users (Millions) |
Growth Rate (2010–2020) |
|
USA |
0.7 |
1.4 |
157.2% |
|
Germany |
0.5 |
1.4 |
184.4% |
|
France |
0.7 |
0.9 |
164.1% |
|
Spain |
0.5 |
0.8 |
173.7% |
|
Australia |
0.4 |
0.6 |
158.4% |
|
Japan |
0.8 |
1.4 |
176.8% |
|
India |
0.5 |
1.3 |
295.6% |
|
China |
0.9 |
1.9 |
214.4% |
Strategic Expansion Models for Market
Feasibility Models for Revenue Growth
|
Country |
Model Type |
Key Driver |
Revenue Impact |
|
India |
Partnership with hospital networks |
Volume bundling & training |
+12.4% (2022–2024) |
|
Germany |
Reimbursement-led model |
DRG-based public funding |
+15.2% YoY (2023) |
|
Japan |
Public-private R&D co-financing |
AMED infrastructure fund |
+11.9% (2023) |
|
China |
Hybrid catheter lab installations |
Provincial insurance support |
+10.2% (2022–2023) |
|
U.S. |
Medicare CPT expansion |
CPT 37213 inclusion, device-drug combos |
+10.5% (2023) |
Challenge
- Patient affordability remains low in emerging markets: In emerging countries like India and some parts of Southeast Asia, the cost for catheter-directed thrombolysis has exceeded USD 2,000.4, which is more than half the average annual income. As per the WHO report, the cost burdens result in over 60.4% of eligible patients being treated in low and middle-income countries. These limitations demand that manufacturers offer a low-cost alternative for the specific drugs. Some organizations, such as Terumo, are developing simple catheter kits to meet the affordability challenge.
Catheter-Directed Thrombolysis Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 745.6 million |
|
Forecast Year Market Size (2034) |
USD 1.9 billion |
|
Regional Scope |
|
Catheter-Directed Thrombolysis Market Segmentation:
Procedure Type Segment Analysis
Within the procedure type segment, the pharmacological thrombolysis sub-segment holds the top position and is anticipated to account for a market share of 42.9% by 2034. Pharmacological thrombolysis is the leading procedure with clinical-wide validation, cost-effectiveness, and a minimally invasive nature. The US National Institutes of Health (NIH) funds broad clinical trials affirming the efficacy and safety of alteplase and tenecteplase, with active grants of over USD 95.8 million (FY 2024) for thrombosis-related research. Furthermore, FDA approvals of site-specific thrombolytics in catheter-directed indication cases have improved physician uptake.
Indication Type Segment Analysis
In the indication type, deep vein thrombosis leads the segment and is expected to hold the market share of 35.7% by 2034. The global increase in aging populations, sedentary lifestyles, and post-COVID immobility syndromes has led to an increase in DVT incidence. As per the CDC report, nearly 60.4% of VTE cases initially originate as DVT, making it the primary clinical indication for catheter-directed thrombolysis. Hospitals prefer catheter-directed thrombolysis for DVT, as it has faster clot resolution, lower hospitalization time, and reduced post-thrombotic syndrome risks.
Our in-depth analysis of the global catheter-directed thrombolysis market includes the following segments:
|
Segment |
Subsegments |
|
Procedure Type |
|
|
Indication |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Catheter-Directed Thrombolysis Market - Regional Analysis
North America Market Insights
The North America catheter-directed thrombolysis market is anticipated to grow steadily and is expected to have a market share of 38.6% at a CAGR of 7.9%. The market is strongly driven by strong healthcare infrastructure, positive reimbursement policy, and increased rates of thrombotic disorders. In 2023, the market reached USD 5.4 billion, which is 9.4% of its federal healthcare expenditure on catheter-directed thrombolysis efforts through institutions such as the CDC, AHRQ, and NIH. Canada came next at USD 3.5 billion, financing growth in interventional radiology facilities. Medicare expenditure increased 15.5% from 2020 to 2024 in the U.S., reaching USD 800.7 million, while Medicaid increased by 10.8%, investing USD 1.6 billion in 2024. North America remains to be the leading region in volume of procedures, adoption of innovation, and clinical education.
The market in the U.S. holds the maximum market share in the North America region. The market is driven by various factors such as robust federal funding, favorable reimbursement, and advanced interventional infrastructure. Medicaid spent USD 1.5 billion in 2024, with the Centers for Medicare & Medicaid Services expanding the reimbursement coverage to treat 10.5% more patients. Additionally, Medicare spending grew 15.3% over the past five years, reaching USD 800.5 million, due to the rise in the elderly and chronic thrombotic disease population. Government actions have also focused on quality-of-care enhancements through AHRQ's guideline suggestions for minimally invasive treatments to lower readmissions and cost pressures.
Asia Pacific Market Insights
The Asia-Pacific catheter-directed thrombolysis market is the fastest-growing region and is expected to hold the market share of 20.8% at a CAGR of 8.6% in 2034. The market is experiencing growth with increased cases of thrombotic disorders, government-sponsored infrastructure developments, and the embracement of minimally invasive treatments among key economies. Japan, China, India, South Korea, and Malaysia are spending on interventional radiology suites, domestic catheter manufacturing, and public-private research initiatives. multinational players are localizing catheter assembly to minimize cost and align with regional procurement preferences. In the APAC market, China and Japan combined hold more than 55% of the regional market share by 2034.
China's catheter-directed thrombolysis market is poised to hold the market share of 28.8% in 2034. As per the NMPA report, China's spending on catheter-directed thrombolysis rose by 15.6% over the past five years. More than 1.7 million patients received CDT treatment in 2023, fueled by rapid expansion across urban hospitals and government-subsidized procedural access through universal health coverage schemes. Strategic collaborations among local manufacturers and public hospitals have brought down the cost of treatments, speeding up adoption across Tier 2 and Tier 3 cities.
APAC Government Investment in Catheter-Directed Thrombolysis (2021–2025)
|
Country |
Year |
Government Policy / Initiative |
Investment / Funding Amount |
|
Australia |
2022 |
National Interventional Radiology Funding Initiative (DoH) |
AUD 220.5 million allocated to thrombolysis units in tertiary hospitals |
|
2024 |
Medicare Benefits Schedule (MBS) expansion for CDT procedures |
AUD 90.3 million/year in procedural reimbursements |
|
|
Japan |
2021 |
AMED Co-funding for CDT device R&D with tertiary hospitals |
JPY 190.8 billion (~USD 1.8 billion) |
|
2024 |
MHLW health strategy: CDT integration in stroke intervention protocol |
JPY 420.6 billion (~USD 3.2 billion) |
|
|
India |
2023 |
Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) – CDT lab development |
INR 14,000.2 crore (~USD 2.2 billion) |
|
2025 |
Ayushman Bharat catheter coverage pilot in 8 states |
INR 3,200.3 crore (~USD 400.6 million) |
|
|
South Korea |
2022 |
HIRA coverage extension for CDT + imaging bundles |
KRW 580.2 billion (~USD 460.6 million) |
|
2025 |
National Strategic Technology Project: advanced catheter systems |
KRW 900.6 billion (~USD 690.3 million) |
|
|
Malaysia |
2021 |
MOH Malaysia’s National Interventional Radiology Modernization Plan |
MYR 500.7 million (~USD 110.6 million) |
|
2023 |
Budget 2023: Additional allocation to expand CDT access |
MYR 200.1 million (~USD 45.4 million) |
Europe Market Insights
The Europe catheter-directed thrombolysis market is expected to have a market share of 28.9% at a CAGR 7.3% in 2034. The EU market is fueled by the strong public investment in vascular health infrastructure, increasing adoption of minimally invasive procedures across leading economies and rising thrombotic disease prevalence. Research and development as well as cross-border clinical cooperation, have been expedited by government-led efforts and EU financing schemes. Germany holds the largest share with €4.4 billion spent in 2024 which is a 12.5% rise in the procedural demand. The France and UK are investing highly in device procurement and procedural capacity. The market in Europe is steadily rising with the support of reimbursement structures, integrated care models, and centralized procurement.
Germany is Europe's largest market for Catheter-Directed Thrombolysis, projected to have a market share of 8.2% in 2034. The market is driven by its well-established hospital infrastructure and high public healthcare spending. In 2024, Germany spent €4.5 billion on CDT treatment and devices, which corresponds to a 12.6% increase in demand since 2021, according to the Federal Ministry of Health (BMG) and BÄK. The German DRG system covers CDT under thoracic and peripheral vascular intervention codes. Clinical practice guidelines issued by the German Society for Vascular Medicine have encouraged CDT as a standard of care in iliofemoral thrombosis. The €1.6 billion strategic government investment in digital health transformation, including real-time monitoring of patients and AI integration within interventional labs, extends CDT procedural volumes further.
Government Investment & Policy in Europe (2021–2025)
|
Country |
Year |
Policy / Program |
Investment / Budget Allocation |
|
United Kingdom |
2023 |
NHS Expansion Plan for CDT under Long Term Plan |
£600 million (€700M) for interventional radiology upgrades |
|
2024 |
NHS National Tariff CDT Coverage (via ABPI collaboration) |
£180 million (€210M) annually for procedural reimbursements |
|
|
France |
2021 |
Plan Innovation Santé 2030 – CDT & Vascular Device Innovation Fund |
€400 million for public R&D and catheter development |
|
2023 |
Expansion of CDT under National Health Insurance |
€2.1 billion allocated for hospital-based procedures |
|
|
Italy |
2022 |
National Recovery and Resilience Plan (NRRP) – Diagnostic Modernization |
€980 million for radiology & interventional tech |
|
2025 |
AIFA-led CDT reimbursement & procurement reform |
€620 million for national catheter supply programs |
|
|
Spain |
2023 |
Public Health Strategic Plan – CDT Implementation in 12 Regions |
€850 million across regional health authorities |
|
2025 |
AEMPS + Ministry of Health vascular initiative |
€500 million for thrombosis treatment infrastructure |
Key Catheter-Directed Thrombolysis Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The world market is dominated by American multinational companies like Medtronic, Boston Scientific, and Penumbra, which collectively command more than 35.6% market share. These companies are heavily investing in R&D, AI image integration, and drug-device combination therapy. European companies like Philips and Biotronik are developing image-guided CDT platforms, while Asian players (e.g., Terumo, MicroPort, and Meril) are increasing regional presence with cost-effective technologies. Strategic partnerships with .gov programs' regulatory acceleration programs, clinical trials, and public health systems are facilitating broader access to CDT, particularly in high-burden areas like APAC and Europe.
The top 20 cohort of such key players includes:
|
Company Name (Country) |
Estimated Market Share (2034) |
Industry Focus |
|
Medtronic plc (USA/Ireland) |
14.5% |
Leading provider of CDT systems, including the Indigo Aspiration System and pharmacomechanical thrombolysis catheters. |
|
Boston Scientific Corporation (USA) |
12.4% |
Offers AngioJet thrombectomy systems widely used in venous thromboembolism management. |
|
Penumbra Inc. (USA) |
9.7% |
Specializes in mechanical thrombectomy systems for peripheral and pulmonary applications. |
|
Becton, Dickinson and Company (USA) |
7.8% |
Manufactures CDT devices and drug-delivery catheters for DVT and PE interventions. |
|
Cook Medical (USA) |
7.5% |
Focuses on CDT with its Zilver Vena catheter portfolio and support for hybrid vascular procedures. |
|
Terumo Corporation (Japan) |
xx% |
Key player in drug-eluting catheters and thrombolytic delivery systems for APAC markets. |
|
Philips Healthcare (Netherlands) |
xx% |
Provides image-guided CDT solutions and vascular access technologies. |
|
Stryker Corporation (USA) |
xx% |
Known for acquisitions in vascular intervention and development of integrated CDT devices. |
|
Teleflex Inc. (USA) |
xx% |
Offers vascular access systems compatible with thrombolysis procedures. |
|
AngioDynamics Inc. (USA) |
xx% |
Pioneer of Uni-Fuse infusion catheters for localized thrombolytic therapy. |
|
MicroPort Scientific (China) |
xx% |
Expanding in mechanical thrombectomy in emerging APAC regions. |
|
Acotec Scientific (China) |
xx% |
Focused on localized thrombolysis and drug-coated catheter systems. |
|
Meril Life Sciences (India) |
xx% |
Indian manufacturer of vascular catheters and thrombolytic delivery systems. |
|
Nipro Corporation (Japan) |
xx% |
Produces catheter-based infusion systems for CDT, expanding across APAC. |
|
Biotronik (Germany) |
xx% |
Known for precision drug-delivery vascular systems and expanding into CDT support products. |
|
Biosensors International (Singapore) |
xx% |
Produces catheters for CDT with drug-eluting microdelivery technologies. |
|
Genesis MedTech (Malaysia) |
xx% |
Regional manufacturer offering CDT-compatible balloon catheters and drug pumps. |
|
Alvimedica (Turkey) |
xx% |
Specializes in interventional catheters for DVT and peripheral vascular disease. |
|
iVascular (Spain) |
xx% |
Offers infusion catheter technologies for targeted thrombolytic delivery. |
|
Universal Biosensors (Australia) |
xx% |
Emerging player in vascular diagnostics and drug-coated catheter systems. |
Here are some leading players in the catheter-directed thrombolysis market:
Recent Developments
- In March 2024, Medtronic launched the TurboJet CDT catheter system, an advanced pharmacomechanical system. Post launch has increased its CDT device sales by 13.7% YoY in Q2 2024.
- In July 2024, Penumbra expanded its Indigo system line with the Lightning Flash, targeting larger clot burdens. The system has showcased a 10.2% revenue growth in Q3 2024.
- Report ID: 4220
- Published Date: Jul 16, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
